Instem plc Exercise of Options, Issue of Equity and TVR (7384E)
March 14 2022 - 1:29PM
UK Regulatory
TIDMINS
RNS Number : 7384E
Instem plc
14 March 2022
14 March 2022
Instem plc
("Instem" or "the Company")
Exercise of Options, Issue of Equity and Total Voting Rights
Instem plc (AIM: INS), a leading provider of IT solutions to the
global life sciences market, announces that it was notified on 14
March 2022 that certain employees of the Company exercised share
options ("Share Options") over, in aggregate, 90,000 ordinary
shares of 10 pence each in the Company ("Ordinary Shares").
Issue of Equity and Admission
Application will be made to the London Stock Exchange for the
admission of the 90,000 new Ordinary Shares to trading on AIM ("New
Ordinary Shares"). Admission is expected to take place at 8.00 a.m.
on 18 March 2022.
Total voting rights
Following the issue and allotment of the above New Ordinary
Shares, the Company's issued share capital comprises 22,379,856
Ordinary Shares. The Company does not hold any Ordinary Shares in
treasury. Therefore the total number of voting rights in the
Company is 22,379,856.
The figure of 22,379,856 may be used by shareholders as the
denominator for the calculations by which they will determine if
they are required to notify their interest in, or a change of their
interest in, the Company under the FCA's Disclosure Guidance and
Transparency Rules.
For further information, please contact:
Instem plc via Walbrook
Singer Capital Markets (Nominated Adviser
& Broker) +44 (0) 20 7496 3000
Peter Steel
Rachel Hayes
Alex Bond
Stifel Nicolaus Europe Limited (Joint
Broker) +44 (0) 20 7710 7600
Ben Maddison
Alex Price
Walbrook Financial PR +44 (0) 20 7933 8780
Tom Cooper instem@walbrookpr.com
Nick Rome
About Instem
Instem is a leading provider of IT solutions & services to
the life sciences market delivering compelling solutions for Study
Management, Regulatory Submissions, Clinical Trial Acceleration,
and Informatics-based Insight Generation.
Instem solutions are in use by over 700 customers worldwide,
including all of the largest 25 pharmaceutical companies, enabling
clients to bring life enhancing products to market faster. Instem's
portfolio of software solutions increases client productivity by
automating study-related processes while offering the unique
ability to generate new knowledge through the extraction and
harmonisation of actionable scientific information.
Instem products and services address aspects of the entire drug
development value chain, from discovery through to market launch.
Management estimate that over 50% of all drugs on the market have
been through some part of Instem's platform during their
development.
To learn more about Instem solutions and its mission, please visit www.instem.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
TVRFLFFDVDISLIF
(END) Dow Jones Newswires
March 14, 2022 13:29 ET (17:29 GMT)
Instem (LSE:INS)
Historical Stock Chart
From May 2024 to Jun 2024
Instem (LSE:INS)
Historical Stock Chart
From Jun 2023 to Jun 2024